Key Findings
Epicrispr Biotechnologies has successfully closed a $90 million Series C financing round, earmarked to accelerate the development of EPI-321, an epigenetic editing drug for facioscapulohumeral muscular dystrophy (FSHD). EPI-321 leverages CRISPR-based tools to modulate gene expression epigenetically, rather than by directly altering DNA sequences, a novel approach designed to silence the genetic driver of FSHD. The company has already completed patient enrollment for an early-stage clinical study of this innovative therapy.
Technical / Clinical Details
EPI-321 specifically targets the aberrant expression of the DUX4 gene, which is the root cause of FSHD. Normally silenced in early development, DUX4 becomes abnormally active in FSHD patients, leading to muscle cell damage and progressive weakness. Epicrispr’s technology employs a modified CRISPR-Cas9 system that combines a guide RNA to direct it to specific DNA regions with an epigenetic modifying enzyme to repress gene expression. This strategy aims to introduce specific epigenetic marks, such as methylation, to the DUX4 gene promoter, effectively turning the gene ‘off’ and thereby preventing the progression of FSHD pathology. A key advantage of this approach is its ability to provide reversible gene control while potentially reducing off-target effects compared to permanent DNA alterations. The initial clinical study focuses on evaluating the drug’s safety, tolerability, and preliminary pharmacodynamic effects.
Background & Context
Facioscapulohumeral muscular dystrophy (FSHD) is a progressive genetic disorder characterized by insidious muscle weakening and wasting, for which no cure currently exists. Patients typically experience initial weakness in facial, shoulder, and upper arm muscles, progressing to affect lower extremities and significantly impairing daily life. While conventional gene therapies often focus on correcting DNA mutations, epigenetic editing offers a new paradigm by adjusting gene function without altering the underlying genetic sequence. This approach distinguishes itself from other gene therapies by offering both precision and potential reversibility, holding immense promise for transforming the treatment landscape of numerous rare diseases.
Strategic Significance & Outlook
The $90 million Series C funding will significantly accelerate the clinical development of EPI-321, bolstering its potential to become the first disease-modifying therapy for FSHD patients. With the successful completion of early-stage clinical enrollment and fresh capital, Epicrispr is well-positioned to advance into larger clinical trials to establish EPI-321’s efficacy and safety. Beyond FSHD, the epigenetic editing technology platform is anticipated to have broad applications across other diseases driven by gene expression dysregulation, including various neurodegenerative disorders and cancers. Epicrispr is poised to deliver groundbreaking solutions for unmet medical needs through this innovative platform, establishing itself as a leader in the next generation of therapeutic technologies.
Source: https://www.biopharmadive.com/news/epicrispr-series-c-epigenetic-editing-fshd/827340/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments